



Statement of GLP Compliance

According to Article 14 paragraph 3 Ordinance on Good Laboratory Practice [OGLP, SR 813.112.1]

The notification authority for chemicals confirms that the following test facility was inspected with respect to the compliance with the Swiss Ordinance on Good Laboratory Practice, adopted on 18th May 2005 [OGLP, SR 813.112.1]. This Ordinance is based on the OECD Principles of Good Laboratory Practice, as revised in 1997 and adopted on 26th November 1997 by decision of the OECD Council [C(97)186/Final].

Unequivocal name and address
of the test facility:

Institute for Biopharmaceutical
Research (IBR), Inc.
Lauchefeld 31

9548 Matzingen, Switzerland

Areas of expertise according to
article 3 paragraph 1 letter d OGLP:

2. mutagenicity studies,
8. analytic and clinical chemistry testing,
9. other studies, described in detail
(pharmacokinetics, immunological testing).

Inspection authority: Swiss Agency for Therapeutic Products (Swissmedic)

Date of inspection: 28 and 29 April 2011

Date of decision: 22 August 2011

Based on the above mentioned decision it can be confirmed that the above mentioned test facility is able to conduct studies according to the aforementioned areas of expertise in compliance with the principles of GLP. The above mentioned test facility is listed in the register and GLP list according to the Article 14 OGLP and is inspected on a regular basis according to Article 6 paragraph 2 OGLP.

Swiss Federal Office of Public Health
Consumer protection directorate
Notification authority for chemicals
CH-3003 Bern



Bern, 27 September 2011, The Head, Dr. Dag Kappes.